中國生物制藥(01177)發布公告，集團附屬公司正大天晴藥業集團股份有限公司(正大天晴)開發的兩款創新藥“鹽酸安羅替尼膠囊”、“TQB2916(CD40激動劑)”將在2024年美國癌癥協會年會(AACR)公布5項研究成果。
臨床研究：
安羅替尼：消化道腫瘤
編號：CT213/13
摘要標題：Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G001-cohort C
安羅替尼：小細胞肺癌
編號：5098/20
摘要標題：Second-line treatment outcomes in Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients after first-line immuno-chemotherapy
TQB2916：晚期惡性腫瘤
編號：CT192/20
摘要標題：A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies
基礎研究：
安羅替尼：甲狀腺髓樣癌
編號：4665/18
摘要標題：USP18 promotes anlotinib resistance in medullary thyroid carcinoma by stabilizing aurora B kinase
安羅替尼：晚期卵巢癌
編號：3997/6
摘要標題：PARP inhibitors plus anlotinib as bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer
jay
